Use of almotriptan in triptan-experienced and triptan-naïve patients.

Use of almotriptan in triptan-experienced and triptan-naïve patients. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Use of almotriptan in triptan-experienced and triptan-naïve patients. Abstract Text:

Julio Pascual,Hans-Christoph Diener,Julio Pascual,Hans-Christoph Diener,

OBJECTIVE: To evaluate the efficacy of oral almotriptan 12.5 mg as an acute treatment for migraine with a focus on triptan-experienced versus triptan-naïve patients. RESEARCH DESIGN AND METHODS: Four recent Almirall-sponsored clinical trials of oral almotriptan 12.5 mg in acute migraine, in which data regarding previous acute therapy were collected, are reviewed. The results and conclusions are limited by the open-label and post hoc design of some of these trials and analyses. RESULTS: In two trials, almotriptan 12.5 mg was used to treat migraine sufferers who were dissatisfied with or were receiving inadequate results with their previous therapy. One of these trials enrolled only patients whose dissatisfaction with their current therapy was confirmed by a validated questionnaire; the other looked at almotriptan 12.5 mg efficacy in patients with previous poor response to sumatriptan. In the other two trials, patients had been achieving satisfactory results with their migraine therapy; one was a randomized, double-blind clinical trial of almotriptan 12.5 mg and zolmitriptan 2.5 mg, the other was an open-label almotriptan 12.5 mg satisfaction trial. Almotriptan 12.5 mg is shown to be effective, well-tolerated, and preferred to previous agents in both patients who were satisfied with, and those who were dissatisfied with, their previous therapy. CONCLUSIONS: Almotriptan should, therefore, not only be considered as first-line therapy for acute migraine but should also be considered for patients who are not satisfied with or not receiving optimal relief from their current acute therapy.

Use of almotriptan in triptan-experienced and triptan-naïve patients. Publishing Authors By Initials

J Pascual,HC Diener,J Pascual,HC Diener,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Use of almotriptan in triptan-experienced and triptan-naïve patients. Journal Published:

PUBLICATION TYPE: Research Support, Non-U.S. Gov

Journal: Current medical research and opinion

VOLUME: 23

Page Numbers: 2433-40

Journal Abbreviation:

ISSN: 1473-4877

DAY: 25

MONTH: Oct

YEAR: 2007

Use of almotriptan in triptan-experienced and triptan-naïve patients. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 351014

Use of almotriptan in triptan-experienced and triptan-naïve patients. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Use of almotriptan in triptan-experienced and triptan-naïve patients. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Use of almotriptan in triptan-experienced and triptan-naïve patients.

AFFILIATION: Service of Neurology, University Hospital, Salamanca, Spain. juliopascual@telefonica.net

Country: England

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Curr Med Res Opin

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Use of almotriptan in triptan-experienced and triptan-naïve patients Related Publications

• A personal view of the classification and definition of drug dependence headache.
• Antiplatelet agents and randomized trials.
• Ca( 2+ )-induced cl (-) efflux at rat distal colonic epithelium.
• Clopidogrel versus aspirin in patients with atherothrombosis: CAPRIE-based calculation of cost-effectiveness for Germany.
• Cortical activation in hemianopia after stroke.
• Effect of active treatment is lower when using placebo control in clinical trials on acute therapy of migraine.
• Effect of carbon dioxide, temperature, and relative humidity on production of aflatoxin in peanuts.
• Efficacy and safety of 1,000 mg effervescent aspirin: individual patient data meta-analysis of three trials in migraine headache and migraine accompanying symptoms.
• How can PET scans help us understand headache mechanisms?
• Low-dose aspirin for migraine prophylaxis in women.
• Low-dose ibuprofen in self-medication of mild to moderate headache: a comparison with acetylsalicylic acid and placebo.
• Placebo in headache trials.
• RPR100893, a substance-P antagonist, is not effective in the treatment of migraine attacks.
• Saccade induced cortical activation in patients with post-stroke visual field defects.
• Se02 the validity of an integrated clinical simulator for learning laparoscopic appendicectomy.
• Stimulation of voltage-dependent Ca2+ channels by NO at rat myenteric neurons.
• Sumatriptan in the treatment of cluster headache.
• Sumatriptan: vasoactive effect on human dural vessels, demonstrated by subselective angiography.
• Systemic Risk Score Evaluation in Ischemic Stroke Patients (SCALA) : A prospective cross sectional study in 85 German stroke units.
• Trigeminal autonomic cephalalgias: a case of post-traumatic SUNCT syndrome?
• Use of almotriptan in triptan-experienced and triptan-naïve patients.
• [Abortion after the 12th completed pregnancy week. Report of experience of a specialist commission]
• [Development of a screening tool for migraine prophylaxis]
• [Incidence of hidden iron deficiency in women, especially in pregnancy and puerperium.]
• [Monitoring stroke units: management, outcome, efficiency]
• [On the applicability of vaginal cytology in the determination of delivery term and in the recognition of prolonged pregnancy]
• [Pathogenesis of anemia in myomas.]
• [Results in the management of pregnancies involving risk factors]
• [Serologic toxoplasmosis control in pregnancy using enzyme immunoassay (EIA). 1st experiences]
• [The change of cervical state during pregnancy (author's transl)]